Abiopharma

🔍 Lang James Paul (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 889 shares of Restricted Stock Units (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 889.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,342 shares of Option to Purchase Common Stock at $70.31 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 1,342.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2026 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
• F2: Represents a stock options granted under the Issuer director compensation program. This grant will vest in full on the date of the Issuer 2026 annual meeting of stockholders.